FDA Grants Breakthrough Therapy Designation for Taiho Oncology's Futibatinib for Treatment of Advanced Cholangiocarcinoma

PRINCETON, N.J. and TOKYO, April 1, 2021 -- (Healthcare Sales & Marketing Network) -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BT... Biopharmaceuticals, Oncology, FDA Taiho Oncology, Taiho Pharmaceutical, futibatinib, cholangiocarcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news